![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Doravirine Efficacy Exposure-Response
Analysis at Week 48 and Implications [poster]
|
|
|
Reported by Jules Levin
16th International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy (IWCPHIVHT) May 26-28, 2015 Washington, DC, USA
Ka Lai Yee,1 Xia Xu,1 Hedy Teppler1
1Merck & Co., Inc., Kenilworth, NJ, USA
![Pharm1.gif](../images/060915/060815-5/Pharm1.gif)
![Pharm2.gif](../images/060915/060815-5/Pharm2.gif)
![Pharm3.gif](../images/060915/060815-5/Pharm3.gif)
![Pharm4.gif](../images/060915/060815-5/Pharm4.gif)
![Pharm5.gif](../images/060915/060815-5/Pharm5.gif)
![Pharm6.gif](../images/060915/060815-5/Pharm6.gif)
![Pharm7.gif](../images/060915/060815-5/Pharm7.gif)
![Pharm8.gif](../images/060915/060815-5/Pharm8.gif)
![Pharm9.gif](../images/060915/060815-5/Pharm9.gif)
![Pharm10.gif](../images/060915/060815-5/Pharm10.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|